Posts by Sandra Ansanay-Alex
Abionic’s test diagnoses sepsis 3 days before the standards methods
Abionic’s test identifies in 5 minutes the earliest signs of sepsis 3 days before the standard of care. The technology just received a European IVDR certification for its in-vitro diagnostics. Abionic SA, a developer of disruptive nanotechnology-based diagnostic solutions, announces that its Pancreatic Stone Protein (PSP) test on the abioSCOPE® has been certified by…
Read MoreObsEva plans job cuts
The ObsEva laboratory is to engage in a vast restructuring process in the face of difficulties encountered with the FDA with its drug in development Linzagolix. Job cuts might be on the agenda. The US Drug Administration (FDA) agreed in November 2021 to review the application for the drug to treat heavy periods associated with…
Read MoreDexter®, the Swiss surgery robot, makes its way to Germany
The Dexter® on-demand robotic surgery system created by the swiss company Distalmotion is now used by the Department for Women’s Health and Gynecology at the University Hospital Tübingen in Germany. Prof. Dr. med. Diethelm Wallwiener, Prof. Dr. med. Sara Brucker, Prof. Dr. med. Bernhard Krämer and their teams used theDexter robot in several surgical…
Read MoreDebiopharm signs an new IDEAL agreement with the University of Geneva
Debiopharms and UNIGE want to fight together against cancer and drug-resistant bacterial infections JULY 25, 2022 Debiopharm, a Swiss biopharmaceutical company based in Lausanne, signed of a new agreement as part of its IDEAL (Innovation Debiopharm Academia Léman) initiative with the University of Geneva (UNIGE). The UNIGE Faculty of Medicine has become a partner of the IDEAL program…
Read MoreUsing proteins as barcodes to fight against counterfeiting
Nanodecoder, an EPFL spin-off, receives CHF 100 000 from FIT The Fondation pour l’Innovation Technologique selection committee announced they have made an Innogrant award of CHF 100 000 to NanoDecoder – an EPFL-based project developing nanopore sensing technologies to fight conterfeiting and perform molecular diagnostics. The startup is working on engineered bio-nanopore providing fast…
Read MoreNestlé Health Science invests EUR 40 million in Enterome
Nestlé Health Science has signed a collaboration agreement with French company Enterome to target food allergies and chronic intestinal diseases Enterome develops new treatments for cancer and autoimmune diseases based on its unique knowledge of the microbiota. With Nestlé Health Science, the french company intends to work on the development of an experimental treatment,…
Read MoreNestlé Health Science and Perseo Pharma partners to fight digestive diseases
Strategic collaboration to create therapies against digestive diseases Perseo pharma, a preclinical stage biopharmaceutical company focused on breaking new ground in enzyme therapies, has entered a strategic research and development collaboration with Nestlé Health Science S.A. to develop up to three programs targeting enzyme deficiencies in patients suffering from digestive diseases. “We are incredibly…
Read MoreADC Therapeutics signs multi-million dollar licensing agreement with Sobi
The swiss and the Swedish companies partner for the development and commercialization of ZYNLONTA®, a drug for hematologic and solid tumors ADC Therapeutics SA has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (Sobi®) for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications outside of the…
Read MoreGnubiotics gets a CHF 1.4 million Innosuisse Grant
The biotech company evaluates the effects of glycopeptides on solid tumors Gnubiotics Sciences, a biotech company pioneering the discovery and development of immunomodulatory glycopeptides based in Biopôle, announced that the Swiss Innovation Agency (Innosuisse) will support a research collaboration with the University Hospital Zürich to accelerate the development of Gnubiotics’ GLAAD technology in a…
Read MoreCHF 4 million for b-rayZ AG, a startup fighting breast cancer
The Tech4Eva alumni and University Hospital Zurich (USZ) uses AI for faster and better breast cancer diagnostics b-RayZ AG has closed an oversubscribed Series A financing round worth over four million Swiss francs with leading investors in the Life Sciences and IT sector. The financing round was led by LifeCare Partners, Protagon AG and…
Read More